🇺🇸 FDA
Pipeline program

SRP-6004

SRP-6004-102

Phase 1 gene_therapy terminated

Quick answer

SRP-6004 for Limb Girdle Muscular Dystrophy is a Phase 1 program (gene_therapy) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Limb Girdle Muscular Dystrophy
Phase
Phase 1
Modality
gene_therapy
Status
terminated

Clinical trials